With three COVID-19 vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.
But a fourth one, under review Tuesday, is entirely different — and it uses a traditional vaccine design that more people may be inclined to trust.
The vaccine, made by Novavax, works just as well as the Pfizer and Moderna vaccines, the company’s studies show. Its side effects seem milder. It’s easier to store. At least 41 other countries — including Australia, Canada, South Korea and the 27 members of the European Union — have approved it. And it enlists the same familiar technique as vaccines against flu, diphtheria, tetanus and whooping cough.
